Esaxerenone vs Steroidal MRAs: Effectiveness and Safety in Clinical Practice

Abstract

Mineralocorticoid receptor antagonists (MRAs) represent a cornerstone in the management of hypertension, heart failure, and chronic kidney disease (CKD). While steroidal MRAs such as spironolactone and eplerenone have long been established, the advent of non-steroidal agents like esaxerenone has prompted a re-evaluation of therapeutic paradigms. This review critically analyzes the effectiveness and safety of esaxerenone in comparison to traditional steroidal MRAs, integrating recent clinical trial data, mechanistic insights, and guideline recommendations to inform optimal clinical practice for healthcare professionals.

Introduction

The renin-angiotensin-aldosterone system (RAAS) is pivotal in the pathogenesis of hypertension and organ damage. MRAs have demonstrated efficacy in mitigating the deleterious effects of aldosterone in cardiovascular and renal diseases. Steroidal MRAs, particularly spironolactone and eplerenone, are widely used but are often limited by adverse effects such as hyperkalemia and endocrine disturbances. Esaxerenone, a novel non-steroidal selective MRA, offers improved receptor selectivity and a promising safety profile. This article provides a comparative assessment of esaxerenone and steroidal MRAs, focusing on their clinical effectiveness, safety considerations, and practical implications in contemporary medical practice.

Epidemiology / Disease Burden

Hypertension affects over one billion individuals globally and is a leading contributor to cardiovascular morbidity and mortality. Furthermore, the prevalence of heart failure and CKD continues to rise, particularly with aging populations and increasing comorbidities such as diabetes. Aldosterone excess, whether primary or secondary, is now recognized as a significant contributor to resistant hypertension and progressive end-organ damage. The widespread impact of these conditions underscores the need for effective and well-tolerated MRAs in clinical practice to reduce the burden of disease and improve patient outcomes.

Pathophysiology

Aldosterone acts via mineralocorticoid receptors (MRs) to promote sodium retention, potassium excretion, inflammation, and fibrosis in cardiovascular and renal tissues. Chronic activation of MRs leads to hypertension, left ventricular hypertrophy, vascular dysfunction, and renal injury. While steroidal MRAs antagonize these effects by competitively inhibiting the MR, their lack of selectivity for steroid receptors can mediate off-target endocrine effects. Esaxerenone, by contrast, is engineered for high selectivity and potency at the MR, with minimal activity at androgen, progesterone, or glucocorticoid receptors, potentially reducing adverse endocrine events.

Risk Factors

Risk factors for aldosterone-driven disease include genetic predisposition, chronic kidney disease, diabetes mellitus, obesity, and primary aldosteronism. Patients with resistant hypertension or heart failure with reduced ejection fraction are particularly likely to benefit from MR blockade. However, susceptibility to MRA-related side effects, especially hyperkalemia, is heightened in elderly individuals, those with impaired renal function, and patients on concomitant RAAS inhibitors.

Clinical Features

Patients with hyperaldosteronism or MR overactivation typically present with resistant hypertension, hypokalemia, metabolic alkalosis, and features of end-organ damage such as left ventricular hypertrophy or proteinuric kidney disease. Clinical presentation may be subtle, necessitating high suspicion and targeted diagnostics. The therapeutic response to MRAs often manifests as improved blood pressure control, reduced proteinuria, and attenuation of cardiac remodeling.

Diagnosis

Diagnosis of conditions warranting MRA use relies on clinical evaluation, biochemical assessment (including plasma aldosterone-to-renin ratio), and imaging when indicated. In resistant hypertension, exclusion of secondary causes, particularly primary aldosteronism, is essential. Baseline assessment of renal function and serum potassium is mandatory prior to MRA initiation to mitigate the risk of adverse effects.

Treatment & Management

Steroidal MRAs, particularly spironolactone, remain first-line agents for primary aldosteronism, resistant hypertension, and heart failure with reduced ejection fraction. Eplerenone, with greater selectivity, offers a reduced risk of sex hormone-related adverse effects. Esaxerenone has emerged as a potent alternative, supported by randomized controlled trials demonstrating comparable or superior efficacy in blood pressure reduction and albuminuria attenuation. Importantly, esaxerenone exhibits a more favorable safety profile, with lower incidence of gynecomastia and menstrual irregularities, and a potentially reduced risk of hyperkalemia when used judiciously.

Recent Advances / Emerging Therapies

Recent phase III studies, including ESAX-HTN and ESAX-DN, have established esaxerenone's efficacy in lowering blood pressure and reducing proteinuria in diabetic nephropathy. Its use is expanding in Asian populations, with ongoing trials in global cohorts. Esaxerenone's unique pharmacokinetic profile and high MR selectivity have sparked interest in its role in cardiorenal protection beyond traditional indications, including heart failure with preserved ejection fraction and non-diabetic CKD. Ongoing research is evaluating its long-term safety, particularly regarding hyperkalemia risk in high-risk populations.

Guideline Recommendations

Contemporary guidelines endorse MRAs for resistant hypertension, heart failure, and primary aldosteronism. While spironolactone and eplerenone are recommended as first-line agents, recent updates, particularly in Japan, now include esaxerenone for hypertension and diabetic nephropathy. International guidelines are anticipated to incorporate non-steroidal MRAs as further evidence accrues. Clinical practice should individualize MRA selection based on efficacy, patient comorbidities, and tolerability, with close monitoring of renal function and serum potassium.

Conclusion

Esaxerenone represents a significant advance in MRA therapy, offering potent, selective MR blockade with reduced endocrine side effects compared to steroidal agents. Recent clinical data support its effectiveness in hypertension and chronic kidney disease, with a promising safety profile. While the risk of hyperkalemia remains a concern, particularly in susceptible populations, careful patient selection and monitoring can optimize outcomes. As evidence evolves, esaxerenone is poised to complement or even supplant traditional steroidal MRAs in select clinical settings, underscoring the importance of individualized, evidence-based care in MR antagonist therapy.